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Cardiovascular outcomes after kidney–pancreas and kidney– Some editorials have recently addressed the question
alone transplantation. of whether the risks associated with pancreas/kidney–
Background. This study retrospectively assessed, with an in-
pancreas transplantation, that is, major surgery and im-tention-to-treat analysis, the effect of kidney–pancreas trans-
munosuppression [1–3], are counterbalanced by the posi-plantation (KP) on survival and cardiovascular outcome in type 1
diabetic uremic patients. tive effects on the acute and chronic complications of
Methods. A total of 351 uremic type 1 diabetic patients were diabetes [4]. Furthermore, these procedures seem to be
enrolled on a waiting list for KP: 130 underwent KP transplan-
associated with a higher incidence of cancer and infectiontation, 25 underwent kidney transplantation alone (KA), whereas
than in the general population [5, 6]. Positive effects of196 patients remained on dialysis (WL). The three populations
had similar cardiovascular conditions. Actuarial survival rates transplant, such as an improvement in peripheral neu-
and causes of death were recorded over a period of seven years. ropathy [7], the quality of life, stabilization of retinopathy
Finally, 23 KP and 13 KA patients underwent left radionuclide
[8], and a decrease in glomerular volume of the trans-ventriculography, during a follow-up of four years.
planted kidney, already have been shown [9]. However,Results. In the entire group of 351 patients the seven-year
survival rate was 77.4% for KP, 56.0% for KA and 39.6% for except for the results of Gaber et al, who reported a
WL (KP vs. WL, P  0.01). Cardiovascular death rate was significant improvement of cardiac function by echocar-
7.6% in KP, 20.0% in KA and 16.1% in WL (KP versus WL,
diography in pancreas/kidney transplanted patients upP  0.03; KP vs. KA, P 0.16). In the subsample studied with
to five years, no other studies aimed at evaluating the ef-radionuclide ventriculography, left ventricular ejection fraction
improved in KP, but did not in KA, with significant differences fects of pancreas transplantation on cardiovascular out-
between groups at two and four years. At four years only the come [10, 11]. It is noteworthy that diabetic patients are
KP patients presented normal values of diastolic parameters, at increased risk for cardiovascular morbidity and mor-including the peak filling rate, time-to-peak filling rate, and
tality [12–19], with an estimated cardiovascular deathpeak filling rate/peak ejection rate ratio. Glycated hemoglobin
was negatively associated with the ejection fraction, peak filling rate ranging from 8.9% to 14.9% [12]. Some investigators
rate and peak filling rate/peak ejection rate ratio, and positively suggest that this is related to diffuse peripheral coronary
associated with the time-to-peak filling rate. atherosclerosis, although the question concerning the ex-Conclusions. Normalization of blood glucose metabolism
istence of a specific diabetic cardiomyopathy is still underand improvement of blood pressure control obtained with KP
transplant is associated with positive effects on survival, cardio- discussion [18]. Left ventricular mass has been reported
vascular death rate, and left ventricular function. to be higher in diabetic patients than in controls [14, 15,
19]. Diastolic filling is frequently impaired [14] and hy-
pertension, particularly in diabetic-uremic patients, is still1 See Editorial by Langone and Helderman, p. 2035.
a major problem [3].
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an intention-to-treat analysis, the effect of good glyco-phy, left ventricular function, glycometabolic control.
metabolic control obtained through kidney–pancreas trans-
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Table 1. Characteristics of patients when enrolled (no statistical difference was observed among the three for each of the parameters considered)
Kidney–pancreas Kidney–alone Dialysed type 1
transplanted patients transplanted patients diabetic patients
(N130) (N25) (N196)
Age years 44.01.2 46.91.5 46.50.6
Duration of dialysis months 35.33.3 36.73.1 38.04.1
Duration of diabetes years 24.50.9 25.00.7 30.11.1
Glycated hemoglobin % 11.01.8 11.12.0 11.52.2
Creatinine mg/dL 8.800.49 8.840.63 8.140.33
Total cholesterol mg/dL 223.410.6 208.97.9 216.76.3
Triglycerides mg/dL 180.110.1 183.517.5 197.315.4
Patients on anti-hypertensive therapy % 99 100 98
Coronary artery disease % 17.5 17.5 13.0
Smoking habits % 21.8 20.5 28.3
METHODS kidney–alone patients were on conventional subcutane-
ous insulin therapy (average 48 IU/day). CyclosporinePatients
levels were within the therapeutic range.Between January 1984 and January 1998, 351 type 1 dia-
betic uremic patients were enrolled on our waiting list for Clinical follow-up
kidney–pancreas transplantation; 130 of them underwent
Actuarial survival of patients and grafts was calculatedkidney–pancreas transplantation (KP; 105 whole pan-
up to seven years after transplantation. A complete clini-creas and 25 segmental pancreas). Patients who received
cal and instrumental assessment aimed at evaluating car-only a renal transplantation (25 patients) due to macro-
diovascular conditions (physical examination, ECG, ca-scopic damage at the time of organ harvest, constituted the
rotid and leg arteries’ Doppler sonography, chest x-raykidney alone (KA) group. One hundred and ninety-six
and blood pressure values) was performed yearly in allpatients remained on dialysis and on waiting list (WL)
the transplanted patients. Cardiovascular events (epi-for immunological reasons such as low HLA matching
sodes of angina pectoris with ECG modifications, acuteand/or antilymphocyte antibodies. The clinical character-
myocardial infarction, acute heart failure) were regularlyistics of the three patient populations were similar when
recorded in all patients. Blood pressure was measuredenrolled on the waiting list (Table 1), exclusion criteria
with sphygmomanometer with subjects in the sitting po-being previous strokes, major amputations and severe
sition, and the average of the last two measurements wasdilated cardiomyopathy. Coronary artery disease was
recorded. Hypertension was considered present if anydefined on the basis of resting electrocardiogram (ECG),
of the following conditions were met: systolic blood pres-thallium-201 myocardial perfusion scintigraphy, and cor-
sure of 140 mm Hg or more, diastolic blood pressure ofonarography in patients positive to thallium-201 scintig-
90 mm Hg or more, or reported use of a medication forraphy. None of the patients presented a pathological ejec-
hypertension. The category of medication assessed intion fraction, and none of them presented characteristics
this study were angiotensin-converting enzyme (ACE)compatible with any of New York Heart Association
inhibitors, beta-blockers, and calcium-channel antago-classes for heart failure. Particularly as regards to cardio-
nists [23]. Blood pressure was recorded in each outpa-vascular condition, no differences such as previous myo-
tient control at approximately every three to six months.cardial infarction, lipid status, and smoking habit were
Pancreas and renal function (glycated hemoglobin andevident (Table 1).
serum creatinine) were tested at enrollment and every
Transplantation six months thereafter.
Organs for transplantation were obtained from cadav-
Radionuclide left ventriculographyeric donors through Nord Italia Transplant. Pancreas
From January 1993 to January 1998 all transplanted pa-transplantation was performed as previously described
tients underwent radionuclide left ventriculography stud-[20–22]. All the transplanted patients received the fol-
ies. Only patients with at least four years follow-up, wholowing immunosuppressive treatment: anti-thymoglo-
were not receiving beta blockers and digitalis, and whobulins (IMTIX), cyclosporine 6 mg kg/day, azathioprine
did not develop a myocardial infarction, were considered1 mg kg/day, and prednisone 10 mg/day. Episodes of
for this study (23 KP and 13 KA transplanted patients).renal rejection were treated with pulses of 500 mg of
During this time period 45 patients underwent trans-methylprednisolone. In cases of “steroid-resistant” rejec-
plantation. Four of them died (2 KP and 2 KA), 4 oftion, OKT3 or a course of IMTIX was used. Kidney–
pancreas patients were insulin-independent, whereas them developed cardiovascular complications (2 acute
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Table 2. Pre-transplant characteristics of patients who underwent 0.007). Cardiovascular death rate (acute myocardial in-
radionuclide assessment during the follow-up farction, acute heart failure, lethal arrhythmias) was
Kidney–pancreas Kidney–alone 7.6% in KP, 20.0% in KA patients and 16.1% in dialyzed
transplanted transplanted patients (KP vs. WL, d.f.  1, P  0.03; KP vs. KA,patients patients
d.f.  1, P  0.16). Neoplasms were lethal in 4.6% of(N23) (N13)
the kidney–pancreas and in 4.0% of the kidney–aloneAge years 38.01.5 42.62.5
group (NS). Infections were lethal in 0% of kidney–Duration of dialysis months 26.24.3 35.04.9
Ejection fraction % 67.04.2 63.86.3 pancreas patients, 4.0% of kidney–alone and 4.2% of
Diastolic dysfunctiona 69.5% 84.6% dialyzed patients (NS).Heart rate bpm 76.32.6 82.63.8
Actuarial kidney graft survival at one, four and sevenIschemic ECG 1/23 2/13
Ischemic myocardial scintigraphy 1/23 2/13 years was 93.4%, 87.2%, and 85.2%, respectively, in the
Hypertensive patients 100% 100% kidney–pancreas group, and 95%, 85%, and 70%, respec-
Total cholesterol mg/dL 233.015.7 212.510.7
tively, in the kidney-alone group. Actuarial whole pan-Triglycerides mg/dL 185.414.7 180.829.3
creas survival at one, four, and seven years was 76.7%,Data were expressed as mean  standard error (no significant differences
were found). 70.6%, and 56.6%, respectively. Creatinine levels were
a Assessed with Doppler echocardiography evaluation similar in the two groups of transplanted patients, (KP
vs. KA, 1.3 vs. 1.4 mg/dL, 1.7 vs 1.8 mg/dL, and 1.8 vs
1.9 mg/dL at one, four and seven years, respectively).
myocardial infarction in the KA group and 2 acute heart Glycated hemoglobin was lower in KP than in KA group
failure, 1 in KP and 1 in KA), while one patient required (KP vs. KA, 6.2 vs. 7.9%, 6.3 vs. 8.8%, and 6.2 vs. 8.2%
beta-blocker therapy. Thirty-six patients were eligible at one, four, and seven years, respectively; all P  0.01).
for the study. The enrollment in the two groups was equal over time
The two groups were comparable before transplant and the accrual rate is shown in Figure 2 (KP  8.6
for age, duration of dialysis, total cholesterol, triglyceride transplanted patients per years; KA  1.6 transplanted
levels, ejection fraction and diastolic dysfunction (Table 2). patients per years).
On the day of the test, after a 15 minute rest in recumbent
position, patients underwent radionuclide left ventricu- Cardiovascular outcome in transplanted patients
lography as previously reported [13]. A lower rate of hypertensive patients at one year—but
not at two years—was observed in kidney–pancreas thanStatistical methods
in kidney–alone transplanted patients (Table 3). More-
The primary end point was death of patients. Actuarial over, in the kidney-alone a higher rate of acute heart fail-
survival rate at seven years was calculated for patients ure and myocardial infarction was observed as compared
and grafted organs. The secondary endpoint was cardio- to the kidney–pancreas group (Table 3). No differences
vascular outcome. The baseline data in the two groups were shown for episodes of angina pectoris (Table 3).
of patients were compared by Student t test for unpaired
data, chi-square test for categorical variables and if not Left ventricular function
normal distribution was present Mann-Whitney U test
Ejection fraction, assessed in 23 kidney–pancreas andwas used. Differences in survival were assessed for statis-
in 13 kidney–alone was similar at three months aftertical significance by Kaplan-Meier survival analysis. The
transplantation (Table 4). An improvement was showninfluence of different pre-transplant parameters on sur-
in kidney–pancreas after two and four years of follow-up,vival was assessed with Cox regression analysis, and the
whereas in the kidney–alone group the ejection fractionfrequency of cardiovascular events in the three groups
remained stable (Table 4). Left ventricular diastolic func-was compared by ANOVA. The Spearman rank order
tion assessed at four years was normal in the kidney–test was used to assess correlation between parameters.
pancreas but impaired in the kidney–alone patients (Ta-Data were expressed as means  standard error.
ble 5). In particular, the peak filling rate, peak ejection
rate and peak filling rate/peak ejection rate ratio were
RESULTS normal in the kidney–pancreas group and impaired in
Patients, graft survival and causes of death the kidney–alone group (Table 5). Time-to-peak filling
rate was significantly higher in the kidney–alone groupAt seven years of follow-up, the patient actuarial sur-
than in kidney–pancreas. Heart rate and arterial bloodvival rate was higher in the kidney–pancreas than in the
pressure values were similar in the groups at the timekidney–alone and dialyzed groups (Fig. 1). Cox regres-
of diastolic assessment. Total cholesterol, creatinine andsion analysis showed no correlations between survival
cyclosporine were similar in the groups studied, whereasand duration of type 1 diabetes (d.f.  1, P  0.24),
kidney-pancreas transplanted patients showed lowerduration of dialysis (d.f.  1, P  0.78), cold ischemia
triglicerydes and glycated hemoglobin (Table 5). Thetime of the kidney (d.f.  1, P  0.5), while a significant
value was present for pre-transplant age (d.f.  1, P  hypertension rate was lower in KP patients, although this
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Fig. 1. Patient actuarial survival rate in 130
kidney–pancreas (KP;), in 25 kidney–alone
(KA; ), and in 196 dialyzed type 1 diabetic
(WL;) patients. Kidney–pancreas versus di-
alyzed, P  0.01, d.f.  5.8. Patients included
in the analysis each year for the two groups
of transplanted patients are: year 1, 113 KP
and 23 KA; year 2, 94 KP and 21 KA; year 3,
85 KP and 18 KA; year 4, 73 KP and 16 KA;
year 5, 62 KP and 12 KA; year 6, 47 KP and
9 KA; year 7, 36 KP and 6 KA.
Table 4. Evaluation of ejection fraction and glycated hemoglobin
during the follow-up in 23 kidney–pancreas and 13 kidney–alone
transplanted patients
Kidney–pancreas Kidney–alone
transplanted patients transplanted patients
(N23) (N13)
Glycated Ejection Glycated Ejection
hemoglobin fraction hemoglobin fraction
% % % %
3 months 5.90.1c 67.00.8c 8.50.3c 63.62.7
1 year 5.90.9c 70.11.0a 9.01.3c 65.62.6
2 years 6.00.2c 71.61.1ab 9.10.4c 65.93.1b
4 years 6.00.1c 76.61.1ab 8.60.4c 65.61.4b
a Ejection fraction at 3 months was statistically different versus 1, 2 and 4
years (P  0.001)
b Ejection fraction was statistically different between kidney–pancreas and
kidney–alone at 2 years (P  0.04) and 4 years (P  0.0001)
c Glycated hemoglobin was statistically lower in kidney–pancreas than in kid-
Fig. 2. Distribution by years of kidney-alone (KA; ) and kidney– ney–alone groups during the whole follow-up (P  0.001)
pancreas (KP; ) transplantation at Hospital San Raffaele.
was not significant. In the kidney–alone group, diastolic
abnormalities were positively associated with a higher
Table 3. Rate of hypertensive patients and cardiovascular events after rate of acute heart failure episodes (KP  0 vs. KA 
kidney–pancreas or kidney–alone in uremic type 1 diabetic patients 4, 2  3.6, d.f.  1, P  0.02). Glycated hemoglobin,
evaluated in both groups of transplanted patients wasKidney–pancreas Kidney–alone
transplanted transplanted negatively associated with ejection fraction at two and
patients patients
four years (Fig. 3). Moreover, in transplanted patients,(N130) (N25) P value
glycated hemoglobin was negatively associated with theHypertensive patients 50% 80% 0.01
peak filling rate and the peak filling rate/peak ejectionat 1 year
Hypertensive patients 64% 84% 0.08 rate ratio, while it was positively associated with the
at 2 years time-to-peak filling rate (Fig. 4).Acute myocardial 3% 20% 0.01
infarction (N4/130) (N5/25)
Acute heart failure 3% 20% 0.01 Subanalysis of kidney-alone group
(N4/130) (N5/25)
Kidney–alone group (25 patients) was constituted ofAngina pectoris 2.3% 8% NS
(N3/130) (N2/25) patients who received only the kidney due to macro-
NS is not significant. scopic damage of the pancreas at harvesting. Survival, car-
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Table 5. Left ventricular function and metabolic parameters,
evaluated at 4 years in 23 kidney–pancreas transplanted
patients and in 13 kidney–alone transplanted patients
Kidney–pancreas Kidney–alone
transplanted transplanted
patients patients
(N23) (N13)
Ejection fraction % 76.61.1a 65.61.4a
Peak ejection rate (EDV/sec) 3.940.11a 3.410.14a
Peak filling rate (EDV/sec) 4.330.19a 3.110.18a
Peak filling rate/peak ejection rate 1.110.05b 0.910.03b
Time to peak filling rate msec 153.16.1b 181.914.7b
Heart rate bpm 76.12.4 73.53.7
Blood pressure mm Hg
Systolic 135.34.5 138.23.6
Diastolic 81.12.0 85.23.1
Triglycerides mg/dL 122.510.9b 169.119.6b
Cholesterol mg/dL 224.810.3 235.316.3
Creatinine mg/dL 1.380.09 1.650.21
Glycated hemoglobin % 6.00.1c 8.60.4c
Hypertensive patients 39.1% 69.2%
EDV is end diastolic volume.
Kidney–pancreas vs kidney–alone: a P  0.01; b P  0.05; c P  0.001
Fig. 4. Correlation between left ventricular diastolic parameters and
glycated hemoglobin at four years. (A) Glycated hemoglobin, evaluated
in the entire group of transplanted patients, was negatively related to
peak filling rate (r  0.5, P  0.003) and (B) to the peak filling rate/
peak ejection rate (r  0.4, P  0.02), while (C) it was positively
related to time to the peak filling rate (r  0.4, P  0.02).
diovascular outcomes and cardiovascular events were sim-
ilar between kidney–alone and kidney–pancreas failed
(Table 6). Kidney–pancreas with early failure of the pan-
creas showed follow-up characteristics similar to kidney
alone rather than to kidney–pancreas group (Fig. 5).
DISCUSSIONFig. 3. Correlation between ejection fraction and glycated hemoglobin
at two (A) and four years (B). Glycated hemoglobin, evaluated in Our study demonstrates a favorable role of pancreas
the whole group of transplanted patients, was negatively associated to
transplantation toward slowing the progression of someejection fraction at 2 (r  0.3, P  0.03) and 4 years (r  0.5, P 
0.008). of the features of macrovascular disease in uremic dia-
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Table 6. Cardiovascular outcomes in the three groups of patients
Cardiovascular death rate Acute myocardial infarction Acute pulmonary edema Angina pectoris
N N of deaths N of events
KP 119 9/119 (7.5%) 2/119 (1.6%) 2/119 (1.6%) 2/119 (1.6%)
KA 25 5/25 (20.0%) 4/25 (16.0%) 5/25 (20.0%) 2/25 (8.0%)
KP failed 11 1/11 (9.0%) 2/11 (18.1%) 3/11 (27.2%) 1/11 (9.0%)
Abbreviations are: KP, kidney–pancreas transplanted patients; KA, kidney–alone transplanted patients; KP failed, kidney–pancreas transplanted patients with
pancreas early thrombosis.
plained on the basis of a different transplant accrual rate,
given that the enrollment in the two groups was equal
over time and that the accrual rate does not explain the
results (Fig. 2).
In our study, the improvement of hypertension was
associated with kidney–pancreas transplant and with the
consequent glycometabolic control. This improvement
was no longer significant at two years, probably due to
the long-term effects of cyclosporine administration to
other influencing factors [23, 24]. It was already observed
that kidney–pancreas transplantation exerts a positive
influence on cardiorespiratory reflexes [25] and on sys-
tolic function [10]. It is noteworthy that diastolic filling
is frequently impaired in type 1 diabetic patients [14].
In agreement with Gaber’s findings of a significant im-
provement of cardiac shortening fraction from baseline
to 12 months, a statistical increase of ejection fraction
during the follow-up was evident in the kidney–pancreas
transplanted patients in our series. A stabilization of
systolic function was observed for diabetic kidney–alone
recipients, but throughout the follow-up no statistical
differences were observed in term of ejection fraction.
Fig. 5. Comparison of the actuarial survival (A) and glycated hemoglo- The early improvement of systolic function shown by
bin (B) between the three groups, kidney–pancreas (KP; ), kidney– Gaber in kidney–alone recipients could be underesti-alone (KA; ) and KP failed (KP failed; ) (KP different vs. other 2
groups). mated in our patients, since no radionuclide left ventricu-
lography was performed six months after transplanta-
tion. Furthermore, the improvement of diastolic function
observed in terms of early/active peak velocity and early/betic patients, mainly blood pressure control, heart events
active integral ratio up to five years by the Memphisand cardiac performance. Even if our approach to de-
group, and its association with glycometabolic control,fining coronary artery disease understimates “silent” is-
have been confirmed by our findings [11].chemic disease, given that angiographic disease can be
Our study showed a normal peak filling rate and peakfound in asymptomatic patients with normal echoes and
filling rate/peak ejection rate ratio in patients after kid-normal noninvasive tests.
ney–pancreas transplant, but not in the kidney–aloneClinical characteristics, cardiovascular risk factors and
group. The data observed in the kidney–alone group arethe hypertension rates were similar in the three groups
similar to those observed in uncomplicated type 1 dia-of patients upon entrance into the study, and, therefore,
betic patients with 15 years of disease, as reported in ait can be concluded that the different outcome was the
previous study using the same methods [14]. Striking dif-consequence of the transplant. Our analysis was con-
ferences in volume distribution between the two groups,firmed by the outcomes observed in the subgroup of
as a consequence of bicarbonate loss due to bladderkidney–pancreas failure, which showed that the survival,
diversion of the transplanted pancreas, can be excludedcardiovascular death rate and events were closer to the
because of appropriate bicarbonate administration inkidney–alone group than the kidney–pancreas trans-
these patients.planted patients.
Furthermore, it is unlikely that our results can be ex- The close relationship between metabolic control and
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cardiac function is confirmed by the correlation between plant. This low incidence of cardiovascular events clearly
was associated with an enhanced ejection fraction, betterglycated hemoglobin and cardiac indices when the trans-
planted patients’ data are pooled together. The peak blood pressure control and normalization of diastolic fill-
ing. Therefore, we conclude that the combination of pan-filling rate/peak ejection rate ratio is close to 1 in healthy
subjects, athletes and compensated type 1 diabetic pa- creas transplantation with kidney transplantation improves
survival and cardiovascular outcome in uremic diabetictients; on the contrary it is reduced in coronary and
hypertensive patients [14]. The diastolic index seems to patients.
be more reliable in identifying an underestimated cardiac
dysfunction that could not be detected with the assess- ACKNOWLEDGMENT
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